Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.71 |
| ▸ | PTGES | O14684 | 1/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.55 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359086 | 0.91 | PTGES (0.84) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL16769856 | 0.91 | PTGES (0.84) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL20045163 | 0.89 | AKT1 (0.71) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL4149021 | 0.88 | ABCG2 (0.71) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL20045166 | 0.85 | DYRK1A (0.71) | AKT1PTGESALOX5PTPN1DYRK1A | |
| SCHEMBL4836863 | 0.84 | AKT1 (1.00) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL31691719 | 0.84 | AKT1 (1.00) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL29357680 | 0.83 | ALOX5 (1.00) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL29928945 | 0.83 | ALOX5 (1.00) | AKT1PTGESALOX5PTPN1ABCG2 | |
| SCHEMBL12954625 | 0.83 | ALOX5 (1.00) | AKT1PTGESALOX5PTPN1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121437-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF MULTIPLE MYELOMA, LYMPHOMA, AND LEUKEMIA | LOWE HENRY (US) | 2021-04-29 | — | — | US | disclosed |
| US-20190083452-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | LOTHERA, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20180098961-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS | FLAVOCURE BIOTECH, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180098961-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS | FLAVOCURE BIOTECH, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083452-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | NCSTN, CHLSN, CNTN1 | AKT1 2084/4885PTGES 2629/4885ALOX5 1564/4885 |
| US-20210121437-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF MULTIPLE MYELOMA, LYMPHOMA, AND LEUKEMIA | FYN, SIRT1, SIRT3 | AKT1 1100/4885PTGES 2169/4885ALOX5 2981/4885 |
| US-20180098961-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS | BRDT, BRD4, CKS2 | AKT1 450/4885PTGES 2440/4885ALOX5 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.